The US Food and Drug Administration advisory committee review of a new heart failure indication for Novartis AG’s Entresto (sacubitril/valsartan) had the potential to be a repeat of the panel meeting on Biogen, Inc.’s Alzheimer’s drug aducanumab more than a month earlier.
As was the case with aducanumb, Novartis was coming to the panel with a trial that missed its primary endpoint....